As the United Kingdom continues to move toward its exit from the European Union without an agreed-upon deal, the UK National Institute for Biological Standards and Control has issued new guidance for manufacturers of biologics in preparation for a no-deal Brexit, and the European Medicines Agency issued a new communication to drug makers seeking Brexit-related Type 1 variations to their marketing authorizations.
As the United Kingdom continues to move toward its exit from the European Union without an agreed-upon deal, the UK National Institute for Biological Standards and Control (NIBSC) has issued new guidance for manufacturers of biologics in preparation for a no-deal Brexit.
In the event of a no-deal scenario, the United Kingdom will no longer be subject to EU rules, and NIBSC will become a stand-alone entity. The United Kingdom will require NIBSC to certify batches of biologics before they can be placed on the UK market for any batches that were not certified by the European Union prior to March 29 (though exceptions will be made for batches manufactured and released in Switzerland and Israel, with whom the United Kingdom shares mutual recognition).
After March 29, the United Kingdom will carry out its own batch release of biologics, taking a risk-based approach to laboratory testing. In cases in which no certificates issued by a laboratory on an approved list are available, NIBSC will carry out its own laboratory assessments. NIBSC will use new statutory fees to fund its work.
If drug makers want to market batches of biologics in the United Kingdom after March 29 and they have not already been certified, drug makers will need to send samples and documentation for batches that will be sold in the UK market to NIBSC. While NIBSC will try to meet batch release turnaround times, the institute urges the early submission of documentation, and invites developers to contact NIBSC about interim arrangements that may be necessary for some products.
Also this month, the European Medicines Agency (EMA) issued a new communication to drug makers seeking Brexit-related Type 1 variations to their marketing authorizations. These variations are changes to authorizations that have little or no impact on the quality, safety, or efficacy of medicinal products. The EMA urged drug makers to file their Brexit-related variations as early as possible in March to allow the EMA to process all submissions (and issue confirmation of compliance with regulatory and legal requirements) before March 29.
The EMA says it expects to see more than a 50% increase in the number of variations filed over the next 3 months as companies submit Brexit-related changes to their marketing authorizations.
The new communications come with just 1 month left before Brexit. Recently, during the Medicines for Europe 18th Regulatory and Scientific Affairs Conference in London, United Kingdom, held from January 31 to February 1, a representative from the EMA told meeting attendees that only 27% of all affected centrally authorized products had completed all necessary pre-Brexit changes. As of November 2018, there were 19 products for human use that appeared to be at risk of not making changes in time.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.